Mechanisms for Laser-Induced Rejuvenation
Summary
It has shown that laser wounding of geriatric skin protects it against skin cancer. The purpose of this study is to determine the origin of cells called fibroblasts which are present after treatment with Fractionated Laser Resurfacing (FLR). These cells restore a youth-like ultraviolet B (UVB) response, but where they come from is currently unknown. The study recruits subjects who are scheduled to undergo abdominoplasties to investigate the origin of those cells stimulated by laser treatment.
Arms & interventions
- DeviceFractionated Laser Resurfacing
A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
Outcome measures
Primary
To test if the new fibroblasts that develop in response to fractionated laser resurfacing (FLR) wounding are derived from blood-derived monocytes.
Identify cells in the skin that have been wounded by FLR at 2 weeks and 1 week previously, for cells that co-express markers for both fibroblasts and monocytes by using single cell RNA-sequencing
Time frame: 2 weeks prior to skin removal and 1 week prior to skin removal
To test if possible cells transitioning from monocytes to fibroblasts are found in the top part of the dermis (papillary dermis).
Using tissue RNA-seq, PI will define if co-expressing cells are in the papillary dermis.
Time frame: 2 weeks prior to skin removal and 1 week prior to skin removal
Secondary
To define the number and types of cells populating the skin following fractionated laser resurfacing (FLR) wounding
Time frame: 2 weeks prior to skin removal and 1 week prior to skin removal
To define the locations of the number of cells populating in the skin following fractionated laser resurfacing (FLR) wounding
Time frame: 2 weeks prior to skin removal and 1 week prior to skin removal
To define the locations of the types of cells populating in the skin following fractionated laser resurfacing (FLR) wounding
Time frame: 2 weeks prior to skin removal and 1 week prior to skin removal
Eligibility criteria
Study locations (1)
Pharmacology Translational Unit
Fairborn, Ohio, 45324